Daniel Vaught
Family · Pueblo West, CONPI 1609282482
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 276 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 276 payments — averaging $18.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$934
- Novo Nordisk$342
- Lilly USA, LLC$333
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$329
- Amgen$261
- plus $2K from 31 others
What the payments were for
- Food & beverage$5,16599%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 37 | $1,003 |
| AbbVie | 55 | $934 |
| Novo Nordisk | 21 | $342 |
| Lilly USA, LLC | 25 | $333 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $329 |
| Amgen | 17 | $261 |
| Bayer | 14 | $247 |
| Scilex Pharmaceuticals Inc. | 8 | $125 |
| Pfizer | 7 | $125 |
| Aimmune Therapeutics, Inc. | 5 | $116 |
| Novartis | 6 | $116 |
| Philips North America LLC | 5 | $111 |
| Boehringer Ingelheim | 6 | $109 |
| Nevro Corp. | 4 | $104 |
| Otsuka America Pharmaceutical, Inc. | 4 | $96 |
| GSK | 6 | $96 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $71 |
| Alkermes, Inc. | 3 | $68 |
| Sunovion Pharmaceuticals Inc. | 4 | $64 |
| Astellas Pharma US Inc | 2 | $54 |
| Nestle Healthcare Nutrition Inc. | 3 | $53 |
| Neurocrine Biosciences, Inc. | 2 | $51 |
| Cequr Corporation | 1 | $48 |
| Axsome Therapeutics, Inc. | 2 | $44 |
| Gilead | 2 | $36 |
| Advanced Respiratory, Inc | 2 | $34 |
| Tonix Medicines, Inc. | 1 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Globus Medical | 1 | $26 |
| Sanofi | 1 | $23 |
| Dexcom, Inc. | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Grifols USA, LLC | 1 | $18 |
| Merck | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,212 in reported general payments places this provider in the 95th percentile of 2,182 family providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 118 | $123,234 |
| OzempicSemaglutide | 85 | $103,195 |
| TrulicityDulaglutide | 84 | $96,909 |
| JardianceEmpagliflozin | 100 | $86,880 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 86 | $64,529 |
| VraylarCariprazine Hcl | 30 | $46,997 |
| XareltoRivaroxaban | 36 | $40,488 |
| Spiriva RespimatTiotropium Bromide | 70 | $38,756 |
| EliquisApixaban | 31 | $33,573 |
| Repatha SureclickEvolocumab | 35 | $22,792 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $20,788 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $17,324 |
| SymbicortBudesonide/Formoterol Fumarate | 44 | $16,961 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $15,333 |
| LinzessLinaclotide | 17 | $14,958 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,003 | $157,519186 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat | $109 | $133,748186 claims |
| Novo NordiskOzempic | $342 | $103,19585 claims |
| Lilly USA, LLCTrulicity | $333 | $96,90984 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $96 | $86,041126 claims |
| AbbVieVraylar, Linzess | $934 | $61,95547 claims |
| PfizerEliquis | $125 | $33,57331 claims |
| MerckBelsomra | $16 | $5,07112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,182 family providers in Colorado.
Other family in Pueblo West
- Corinne YoungColorado Springs$272K
- Margaret MachaffieColorado Springs$97K
- April RossGrand Junction$95K
- Jeannette LillerColorado Springs$74K
- Teal MeffordThornton$63K
- Jacquita JordanColorado Springs$52K
- Stephanie HanenbergColorado Springs$40K
- Courtney WeirFort Collins$30K
- Katie NadingDenver$28K
- Randall McDavidDenver$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.